Charles Schwab Corp
Change company Symbol lookup
Select an option...
SCHW-J Charles Schwab Corp
BIOT Biotech Acquisition Co
MICR Micron Solutions Inc
WSBF Waterstone Financial Inc
MBRX Moleculin Biotech Inc
STRNY Severn Trent PLC
BRSP Brightspire Capital Inc
DBX Dropbox Inc
EESH Eestech Inc
GRTS Gritstone bio Inc

Financials : Capital Markets | Large Cap Growth
Company profile

The Charles Schwab Corporation is a savings and loan holding company. The Company, through its subsidiaries, engages in wealth management, securities brokerage, banking, asset management custody, and financial advisory services. The Company provides financial services to individuals and institutional clients through two segments: Investor Services and Advisor Services. The Investor Services segment provides retail brokerage, investment advisory, and banking and trust services to individual investors, and retirement plan services. The Advisor Services segment provides custodial, trading, banking and trust, and support services, as well as retirement business services to independent registered investment advisors (RIAs), independent retirement advisors and recordkeepers. The Company’s product offerings include brokerage, mutual funds, exchange-traded funds (ETFs), advice solutions, banking and trust.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
0.27 (1.44%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Cybin to Participate in Upcoming Scientific and Investor Conferences

8:00 am ET September 21, 2022 (BusinessWire) Print

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is pleased to announce its participation in the following upcoming conferences:

Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event, September 21, 2022 in Haarlem, Amsterdam

Doug Drysdale, Cybin's Chief Executive Officer, participated in a panel discussion titled "Trials to Treatments" at 10:00 a.m. Central European Time on Wednesday, September 21, 2022.

Interdisciplinary Conference on Psychedelic Research, September 22-24, 2022 in Haarlem, Amsterdam

Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin's Chief Medical Officer, will participate in a panel discussion titled "Where Psychedelics Science Meets Business" at 10:30 a.m. Central European Time on Saturday, September 24, 2022. For more information on how to access the event, please click here. Bill Brennan, Ph.D., Co-Author of EMBARK, and a core faculty and clinical supervisor, will deliver a presentation on Cybin's psychedelic-assisted psychotherapy model titled "Introducing EMBARK: a trans-diagnostic, trans-drug model of psychedelic-assisted psychotherapy and therapist training" at 2:40 p.m. Central European Time on Friday, September 23, 2022.

Jefferies Innovation in Mental Health Summit, September 22, 2022 in New York City, NY

Leah Gibson, Cybin's Vice President of IR & Strategic Communications, will host investor meetings. If you plan on attending the conference, please reach out to your Jefferies representative to request a meeting.

Cantor Neurology & Psychiatry Conference, October 6-7, 2022, in San Francisco, CA

Doug Drysdale, Cybin's Chief Executive Officer, will participate in a panel discussion and host investor meetings. If you plan on attending the conference, please reach out to your Cantor representative to request a meeting.

About Cybin Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on

SOURCE: Cybin Inc.

Investor & Media: 
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc. - or - 

Gabriel Fahel
Chief Legal Officer
Cybin Inc.
comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.